Statement Before the Judiciary Committee

Alex Brill | House Committee on the Judiciary

My testimony will address 4 topics:

1. The size, scope and importance of the biologic drug industry;

2. A framework for understanding the likely market dynamics for biogeneric competition;

3. An economic model for understanding the appropriate amount of exclusivity to provide innovator biologic drugs;

4. Views on proper data exclusivity, tiered exclusivity schemes and the negative consequences from granting “too much” exclusivity

To avoid the building of any undue suspense, I will begin with my conclusion. Biologic drugs offer great promise for improving outcomes in healthcare. While they are costly, time consuming and risky products to develop, they offer some of the best hopes for treating some of the nation’s most deadly and debilitating diseases.

Read Here